Recro Pharma, Inc.
490 Lapp Road
Tek Park Building
Malvern
Pennsylvania
19355
United States
Tel: 484-395-2470
Fax: 484-395-2471
Website: http://www.recropharma.com/
Email: info@recropharma.com
About Recro Pharma, Inc.
Recro Pharma is a revenue-generating, specialty pharmaceutical company focused on products for hospitals and ambulatory care settings that is currently developing non-opioid products for the treatment of acute pain. Our lead product candidate is a proprietary injectable form of meloxicam. Intravenous, (IV), meloxicam has successfully completed multiple Phase II clinical trials for the treatment of moderate to severe pain.
LEADERSHIP:
CEO: Gerri Henwood
CFO: Michael Celano
CMO: Stewart McCallum
CCO: Fred Graff
JOBS:
Please click here for Recro Pharma.
CLINICAL TRIAL:
62 articles about Recro Pharma, Inc.
-
Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation
3/21/2022
Recro Pharma, Inc. today announced that it is changing its name to Societal CDMO, Inc. to reflect the corporate transformation that has taken place primarily as a result of its acquisition and successful integration of IriSys, Inc. into the organization.
-
Recro Reports Fourth Quarter and Year End 2021 Financial Results
3/1/2022
Recro Pharma, Inc. today reported financial results for the fourth quarter and year ended December 31, 2021.
-
Recro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego FacilityFull Scope of New Service Capabilities to be Operational in Q2; Company Has Already Secured Project Commitments from Multiple New Clients
2/23/2022
Recro Pharma, Inc. reported key progress in adding fill/finish and lyophilization capabilities to its broad suite of CDMO offerings.
-
Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022
2/22/2022
Recro Pharma, Inc. announced that the company will release financial results for the fourth quarter and year-end 2021 after the market close on Tuesday, March 1, 2022.
-
Recro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of Topical Treatment for Skin Cancer Prevention
1/26/2022
Recro Pharma, Inc. today announced that it has been awarded a new formulation development and cGMP manufacturing contract from a key department of the United States government.
-
BioSpace Movers & Shakers, Jan. 21
1/21/2022
Biopharma and life sciences companies made numerous appointments this week to boards and executive teams. These Movers & Shakers will position the companies for future growth. -
Recro Appoints Eduardo Uribe as Head of Quality for Recro San Diego
1/19/2022
Recro Pharma, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, announced the appointment of Eduardo Uribe as the company’s head of quality for Recro San Diego.
-
Recro Reports Inducement Grants For New Staff - Jan 06, 2022
1/6/2022
Recro Pharma, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, announced the addition of new employees to fill open roles in technical operations.
-
Recro to Present at H.C. Wainwright BioConnect 2022 Conference
1/3/2022
Recro Pharma, Inc. today announced that its chief executive officer, David Enloe, will deliver a corporate presentation as part of the H.C. Wainwright BioConnect 2022 Conference.
-
Recro to Present at Stephens Annual Investment ConferenceFireside Chat Webcast Available
12/2/2021
Recro Pharma, Inc. today announced that its chief executive officer, David Enloe, will participate in a fireside chat as part of the Stephens Annual Investment Conference | NASH2021.
-
Recro Reports Third Quarter 2021 Financial Results
11/9/2021
Recro Pharma, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, reported financial results for the third quarter and nine months ended September 30, 2021.
-
Recro to Report Financial Results for Third Quarter 2021 on November 9, 2021Conference Call and Webcast Scheduled for Tuesday, November 9, 2021 at 4:30 p.m. Eastern
11/2/2021
Recro Pharma, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, announced that the company will release financial results for the third quarter 2021 after the market close on Tuesday, November 9, 2021.
-
Recro Enters Into Master Commercial Supply and Services Agreement With Otsuka
10/27/2021
Recro Pharma, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, announced the signing of a master supply and services agreement with Otsuka Pharmaceutical Co., Ltd.
-
Recro Awarded Development and Manufacturing Contract by National Institutes of Health (NIH) to Support Novel Nasal Spray Analgesic
10/20/2021
Recro Pharma, Inc. announced that it has been awarded a new development and manufacturing contract by the National Center for Advancing Translational Sciences at the National Institutes of Health.
-
BioSpace Movers & Shakers, Oct. 8
10/8/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Recro Reports Inducement Grants For New StaffHighlights Appointment of New Vice President and Site Head of Operations for Recro San Diego
10/6/2021
Recro Pharma, Inc. today announced the expansion of its team through the addition of new employees to support product development, business development, quality, technical operations
-
Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
9/8/2021
Recro Pharma, Inc. and BioCorRx, Inc. announced the expansion of the companies’ ongoing relationship with the signing of a new development and manufacturing agreement.
-
Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS
8/17/2021
Recro Pharma, Inc. announced that company management will host a webcast to discuss the company’s recently announced acquisition of IRISYS, a San Diego-based CDMO that possesses capabilities that complement and expand those of Recro.
-
Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO
8/13/2021
Recro Pharma, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, announced its acquisition of IRISYS, a San Diego-based CDMO that possesses capabilities that complement and expand those of Recro.
-
Recro Announces Entry Into Letter of Intent for Acquisition of a Full Service CDMO
8/10/2021
Recro Pharma, Inc. announced that it has signed a non-binding letter of intent for its acquisition of a full service CDMO with capabilities that range from formulation development to commercial manufacturing for various dosage forms including oral liquids, sterile injectables, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes and nano/microparticles.